-
FDA Approves Ferring Pharmaceuticals’ Degarelix (Generic Name) for Treatment of Advanced Prostate Cancer
-Ferring Pharmaceuticals, USA today received approval from the U.S. Food and Drug Administration (FDA) for degarelix…
0 -
Committee for Medicinal Products for Human Use (CHMP) recommends granting marketing authorisation for FIRMAGON® (degarelix) for treatment of prostate cancer
-Ferring Pharmaceuticals received today notification that the Committee…
-
Ferring and Conaris complete license agreement for new recombinant molecule in gastroenterology
-Ferring Pharmaceuticals and Conaris Research Institute AG today announced that they have completed…
-
Ferring signs distribution agreement with BioGaia in Ireland and the Middle East
-BioGaia has extended its collaboration with the Swiss biopharmaceutical company Ferring Pharmaceuticals giving Ferring exclusive rights to sell BioGaia’s Probiotic Drops in Ireland and…
-
Auxilium Pharmaceuticals, Inc. Announces Distribution and License Agreement for Testim® in Europe with Ferring Pharmaceuticals
-Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) and Ferring International S.A. today announced…
-
Positive phase III data unveiled for new GnRH blocker degarelix
-Data from a Phase III study presented at the 23rd Annual European Association of Urology Congress demonstrated that the investigational GnRH blocker, degarelix…
-
Ferring Pharmaceuticals submits new drug application for degarelix, a prostate cancer treatment
-Ferring Pharmaceuticals announced today that it has submitted applications in Europe and the United States for…
-
Launch of new, prestigious infertility and gynaecology research grant (FRIGGA) at “Update in Infertility 2008”
-Ferring Pharmaceuticals today launches the first Ferring Research Infertility and Gynaecology GrAnt (FRIGGA) for fundamental fertility and gynaecology research…
Archive for 2008
2008